Sutro Biopharma (STRO) Net Income towards Common Stockholders (QoQ) (2017 - 2025)
Sutro Biopharma (STRO) Net Income towards Common Stockholders (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Sutro Biopharma | 206.03 Mn | 64.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.77% |
| Sep 30, 2025 | -394.45% |
| Jun 30, 2025 | 83.00% |
| Mar 31, 2025 | 6.65% |
| Dec 31, 2024 | -48.49% |
| Sep 30, 2024 | -1.60% |
| Jun 30, 2024 | 17.51% |
| Mar 31, 2024 | -287.44% |
| Dec 31, 2023 | 163.02% |
| Sep 30, 2023 | -27.93% |
| Jun 30, 2023 | 23.03% |
| Mar 31, 2023 | -44.68% |
| Dec 31, 2022 | -77.51% |
| Sep 30, 2022 | 25.08% |
| Jun 30, 2022 | 33.49% |
| Mar 31, 2022 | -2.58% |
| Dec 31, 2021 | -23.37% |
| Sep 30, 2021 | -402.31% |
| Jun 30, 2021 | 68.72% |
| Mar 31, 2021 | 23.73% |